Westham Competitors and Similar CompaniesClear all

Westham's competitors and similar companies include Alnylam Pharmaceuticals, Merus and Aerie Pharmaceuticals.
Westham
Westham
Westham is a biotech company that provides mosquito control solutions.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.
Merus
Merus
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients.
Aerie Pharmaceuticals
Aerie Pharmaceuticals
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
Founding Date
Founding Date
2006
Founding Date
2002
Founding Date
2003
Founding Date
2005
Type
Type
Private
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Dallas, US HQ
Hod Hasharon, IL
Locations
Cambridge, US HQ
Paris, FR
Milan, IT
Tokyo, JP
Amsterdam, NL
Stockholm, SE
Zug, CH
see more
Locations
Utrecht, NL HQ
Cambridge, US
Locations
Irvine, US HQ
Dublin, IE
千代田区, JP
Henley On Thames, GB
Bedminster, US
Durham, US
Employees
Employees
918% decrease
Employees
1,32324% increase
Employees
1725% increase
Employees
3808% increase
Valuation ($)
Valuation ($)
N/A
Valuation ($)
18.8 b
Valuation ($)
2.4 b
Valuation ($)
722.2 m

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$1.8b (FY, 2023)
Revenue (est.)
$43.9m (FY, 2023)
Revenue (est.)
$194.1m (FY, 2021)
Cost of goods
Cost of goods
N/A
Cost of goods
$268.2m (FY, 2023)
Cost of goods
N/A
Cost of goods
$26.8m (FY, 2021)
Gross profit
Gross profit
N/A
Gross profit
$1.6b (FY, 2023)
Gross profit
$43.9m (FY, 2023)
Gross profit
N/A
Net income
Net income
N/A
Net income
($440.2m) (FY, 2023)
Net income
($154.9m) (FY, 2023)
Net income
($74.8m) (FY, 2021)

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 1.5b
Total funding raised
$ 149.3m
Total funding raised
$ 388.6m
For sources of this data, please see the company profile

View Company Profiles

Alnylam Pharmaceuticals
HQ
Cambridge, US
Employees
1,323↑ 24% increase

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.

View company
Merus
HQ
Utrecht, NL
Employees
172↑ 5% increase

Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients.

View company
Aerie Pharmaceuticals
HQ
Irvine, US
Employees
380↑ 8% increase

Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.

View company